Gemayel Lee1, Brittany Grovey2, Tim Furnish2, Mark Wallace2. 1. Center for Pain Medicine, University of California, San Diego, 9300 Campus Point Drive, Mail Code 7651, La Jolla, CA, 92037, USA. Gemayel.LeeMD@gmail.com. 2. Center for Pain Medicine, University of California, San Diego, 9300 Campus Point Drive, Mail Code 7651, La Jolla, CA, 92037, USA.
Abstract
PURPOSE OF REVIEW: Many cultures throughout history have used cannabis to treat a variety of painful ailments. Neuropathic pain is a complicated condition that is challenging to treat with our current medications. Recent scientific discovery has elucidated the intricate role of the endocannabinoid system in the pathophysiology of neuropathic pain. As societal perceptions change, and legislation on medical cannabis relaxes, there is growing interest in the use of medical cannabis for neuropathic pain. RECENT FINDINGS: We examined current basic scientific research and data from recent randomized controlled trials (RCTs) evaluating medical cannabis for the treatment of neuropathic pain. These studies involved patients with diverse etiologies of neuropathic pain and included medical cannabis with different THC concentrations and routes of administration. Multiple RCTs demonstrated efficacy of medical cannabis for treating neuropathic pain, with number needed to treat (NNT) values similar to current pharmacotherapies. Although limited by small sample sizes and short duration of study, the evidence appears to support the safety and efficacy of short-term, low-dose cannabis vaporization and oral mucosal delivery for the treatment of neuropathic pain. The results suggest medical cannabis may be as tolerable and effective as current neuropathic agents; however, more studies are needed to determine the long-term effects of medical cannabis use. Furthermore, continued research to optimize dosing, cannabinoid ratios, and alternate routes of administration may help to refine the therapeutic role of medical cannabis for neuropathic pain.
PURPOSE OF REVIEW: Many cultures throughout history have used cannabis to treat a variety of painful ailments. Neuropathic pain is a complicated condition that is challenging to treat with our current medications. Recent scientific discovery has elucidated the intricate role of the endocannabinoid system in the pathophysiology of neuropathic pain. As societal perceptions change, and legislation on medical cannabis relaxes, there is growing interest in the use of medical cannabis for neuropathic pain. RECENT FINDINGS: We examined current basic scientific research and data from recent randomized controlled trials (RCTs) evaluating medical cannabis for the treatment of neuropathic pain. These studies involved patients with diverse etiologies of neuropathic pain and included medical cannabis with different THC concentrations and routes of administration. Multiple RCTs demonstrated efficacy of medical cannabis for treating neuropathic pain, with number needed to treat (NNT) values similar to current pharmacotherapies. Although limited by small sample sizes and short duration of study, the evidence appears to support the safety and efficacy of short-term, low-dose cannabis vaporization and oral mucosal delivery for the treatment of neuropathic pain. The results suggest medical cannabis may be as tolerable and effective as current neuropathic agents; however, more studies are needed to determine the long-term effects of medical cannabis use. Furthermore, continued research to optimize dosing, cannabinoid ratios, and alternate routes of administration may help to refine the therapeutic role of medical cannabis for neuropathic pain.
Entities:
Keywords:
CBD; Cannabinoid; Cannabis; Medical marijuana; Neuropathic pain; THC
Authors: Mark J Pletcher; Eric Vittinghoff; Ravi Kalhan; Joshua Richman; Monika Safford; Stephen Sidney; Feng Lin; Stefan Kertesz Journal: JAMA Date: 2012-01-11 Impact factor: 56.272
Authors: Caroline Schaefer; Alesia Sadosky; Rachael Mann; Shoshana Daniel; Bruce Parsons; Michael Tuchman; Alan Anschel; Brett R Stacey; Srinivas Nalamachu; Edward Nieshoff Journal: Clinicoecon Outcomes Res Date: 2014-10-29
Authors: Grace A Kanzawa-Lee; Robert Knoerl; Clare Donohoe; Celia M Bridges; Ellen M Lavoie Smith Journal: Semin Oncol Nurs Date: 2019-04-30 Impact factor: 2.315
Authors: John S Luque; Arinze Nkemdirim Okere; Carlos A Reyes-Ortiz; Paula M Williams Journal: Complement Ther Med Date: 2021-01-15 Impact factor: 2.446
Authors: Jan M Schilling; Chloe G Hughes; Mark S Wallace; Michelle Sexton; Miroslav Backonja; Tobias Moeller-Bertram Journal: J Pain Res Date: 2021-05-05 Impact factor: 3.133
Authors: Kevin H Yang; Christopher N Kaufmann; Reva Nafsu; Ella T Lifset; Khai Nguyen; Michelle Sexton; Benjamin H Han; Arum Kim; Alison A Moore Journal: J Am Geriatr Soc Date: 2020-10-07 Impact factor: 5.562